Ecodesign is one of the basic pillars of the new circular economy promoted by the European Union with the aim that products, goods, and resources remain in the economy for as long as possible minimize the generation of the waste. In this context, Inno4Life.com joins the promotion of the circular economy with the launch of this new website, focused on the application of ecodesign in pharmaceutical packaging.

The company seeks with this space to make known to the public opinion this work methodology that, from the initial phase of product design, analyzes the impact it will have on the environment during all stages of its life cycle, from the selection of its materials until their end of life and recycling. To do this, it is committed to explaining in a dynamic and simple way the environmental, economic, market, image, and quality advantages that the application of the circular economy brings to the design of pharmaceutical packaging.

 we want the citizens to know and become familiar with the concept of ecodesign and advantages of ecodesign, one of the basic pillars of the new circular economy promoted by the European Union, and how it contributes to building a more sustainable society,

Inno4Life Eco design website, developed by Ecoavantis, also includes examples of environmental initiatives that, through our Business Packaging Prevention Plans, have been applied by the pharmaceutical industry in recent years and have managed to reduce the average weight of pharmaceutical packaging by 22.85%. that are annually put on the market. In this way, good practices are offered that can inspire other pharmaceutical laboratories that want to bet on being more responsible with the environment and adapting to the global challenges that arise in society.

Pharmaceutical packaging: safety in all aspects

The fundamental principle of companies in the pharmaceutical industry, as well as related packaging companies, is "no compromise on product safety". When you are so close to people, it is strictly controlled and multiple conditions and directives must be met. There are no small challenges for companies. From an economic point of view, this sector benefits from a stable growth market. The German pharmaceutical market occupies the leading position in Europe and with annual sales of just over 50,000 million euros, it is the fourth in the world. But here too the industry must catch up.

The increase in life expectancy, the growth of chronic diseases and the introduction of new and often very expensive forms of therapy have led to good growth in recent years. More and more diseases can be treated. Also for infrequent diseases, of which there are comparatively small numbers of cases, drugs that require more complexity from manufacturers with increasingly smaller batch sizes are developed more and more frequently.

Published by Shahbaz Ahmed